FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And Lymphocytes
美國食品藥品管理局批准X4製藥公司的Xolremdi(Mavorixafor)膠囊,用於12歲及以上的WHIM綜合徵患者,以增加循環中的成熟中性粒細胞和淋巴細胞的數量